FASN and metabolic dysfunction-associated steatohepatitis: Specifically, we selected the FASN inhibitor TVB-3664 which is the mouse compatible analogue of TVB-2640, a first-in-class orally bioavailable FASN inhibitor in Phase 2 clinical trial for nonalcoholic steatohepatitis (NASH) and with potential antineoplastic indications [25, 26].